Showing 6651-6660 of 10157 results for "".
- Ortho Dermatologics Receives Tentative FDA Approval for Bryhali for Plaque Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-received-tentative-fda-approval-for-bryhali-for-plaque-psoriasis/2457575/The FDA has provided tentative approval of the New Drug Application for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. Bryhali Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate i
- Acne Stigma Linked to Lower Overall Q of Lhttps://practicaldermatology.com/news/acne-stigma-linked-to-lower-overall-q-of-l/2457578/Acne patients perceived social stigma negatively affects their quality of life, according to a new study from the University of Limerick. In the survey of 271 people with acne, those whose negative perceptions of how society viewed their appearance had higher psychological distress levels
- Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychiahttps://practicaldermatology.com/news/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia/2457580/Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment
- Ortho Dermatologics' Bryhali Lotions Performs Well in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ortho-dermatologics-psoriasis-drug-bryhali-performs-well-in-two-phase-3-trials/2457585/Two Phase 3 randomized controlled trials show that Bryhali (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent corticosteroid in the treatment of moderate-to-severe plaque psoriasis, is effective and well-tolerated. Bryhali Lotion has a Prescription Drug
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to laun
- Candela and Vascular Birthmark Foundation Offer Pro Bono Laser Treatments for Patients in Needhttps://practicaldermatology.com/news/candela-and-vascular-birthmark-foundation-offer-pro-bono-laser-treatments-for-patients-in-need/2457593/Candela Corporation is partnering with the Vascular Birthmarks Foundation (VBF) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related skin conditions as a kickoff to the VBF 18th A
- Scar-Less Healing May be on the Horizonhttps://practicaldermatology.com/news/scar-less-healing-may-be-on-the-horizon/2457595/Stromal cell-derived-factor-1 (SDF1), a compound secreted in the bloodstream, may be the key factor that causes wounds in older people to heal with less scarring than in younger people, according to researchers from the Perelman School of Medicine at the Univer
- With Launch of TruSculpt ID, Cutera Defines Today's Body Contouring Patienthttps://practicaldermatology.com/news/with-launch-of-trusculpt-id-cutera-defines-todays-body-contouring-patient/2457594/A third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results were released to coincide with the availability of truSculpt iD, a non-
- Kuleana Debuts Natural, Reef-Safe Sunscreenhttps://practicaldermatology.com/news/kuleana-debuts-natural-reef-safe-sunscreen/2457601/Amid growing concerns that certain sunscreen ingredients are harming coral reefs and marine life, Hawaiian company Kuleana is rolling out a natural sunscreen that is free from oxybenzone and octinoxate – two chemicals known to be toxic to corals and other marine life that were recently bann
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women wit